Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 50 entries
View as:

Tumour Registry Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00910819 Org: User:
Start: 09/30/06 End: 03/31/22 Due: 03/31/23

Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02537808 Org: User:
Start: 06/23/15 End: 09/13/23 Due: 09/13/24

Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone

Phase: N/A Priority: Normal
NCT ID: NCT00911105 Org: User:
Start: 05/31/09 End: 11/30/15 Due: 11/30/16

Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02970747 Org: User:
Start: 10/25/16 End: 06/30/25 Due: 06/30/26

Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Phase: N/A Priority: Normal
NCT ID: NCT04389541 Org: User:
Start: 04/17/20 End: 06/30/23 Due: 06/30/24

Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

Phase: N/A Priority: Normal
NCT ID: NCT03619993 Org: User:
Start: 06/25/18 End: 09/10/19 Due: 09/10/20

Clinical Tumor Anemia Registry (TAR)

Phase: N/A Priority: Normal
NCT ID: NCT01795690 Org: User:
Start: 12/31/11 End: 02/29/16 Due: 02/28/17

Registry Platform Ovarian and Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05129969 Org: User:
Start: 11/25/21 End: 12/31/30 Due: 12/31/31

Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)

Phase: N/A Priority: Normal
NCT ID: NCT05284591 Org: User:
Start: 07/06/22 End: 09/20/24 Due: 09/20/25

Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

Phase: N/A Priority: Normal
NCT ID: NCT06181734 Org: User:
Start: 12/20/23 End: 12/30/28 Due: 12/30/29

Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

Phase: N/A Priority: Normal
NCT ID: NCT04557813 Org: User:
Start: 12/02/20 End: 12/31/24 Due: 12/31/25

Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02410044 Org: User:
Start: 12/23/14 End: 08/16/20 Due: 08/16/21

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05326308 Org: User:
Start: 04/26/22 End: 08/31/28 Due: 08/31/29

Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02537743 Org: User:
Start: 08/19/15 End: 02/19/21 Due: 02/19/22

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

Phase: N/A Priority: Normal
NCT ID: NCT04290806 Org: User:
Start: 12/04/19 End: 12/31/28 Due: 12/31/29

Non-interventional Study With Azacitidin (Vidaza®)

Phase: N/A Priority: Normal
NCT ID: NCT01192945 Org: User:
Start: 07/31/10 End: 11/30/15 Due: 11/30/16

Registry Platform Myelofibrosis and Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06976918 Org: User:
Start: 09/30/25 End: 09/30/31 Due: 09/30/32

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03811418 Org: User:
Start: 01/31/19 End: 04/30/19 Due: 04/30/20

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01521715 Org: User:
Start: 01/24/12 End: 07/31/17 Due: 07/31/18

Tumor Registry Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02089269 Org: User:
Start: 12/31/13 End: 06/30/24 Due: 06/30/25

Tumour Registry Lung Cancer (TLK)

Phase: N/A Priority: Normal
NCT ID: NCT01192919 Org: User:
Start: 01/31/10 End: 07/31/16 Due: 07/31/17

Ripretinib (QINLOCK®) According to Current SmPC

Phase: N/A Priority: Normal
NCT ID: NCT06619275 Org: User:
Start: 10/17/24 End: 11/30/27 Due: 11/30/28

Registry Platform Urologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03374267 Org: User:
Start: 12/07/17 End: 06/30/27 Due: 06/30/28

Fruquintinib in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06787105 Org: User:
Start: 02/17/25 End: 12/31/27 Due: 12/31/28

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT06043011 Org: User:
Start: 09/27/23 End: 12/31/33 Due: 12/31/34